首页> 外文OA文献 >Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma

【2h】

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma

机译：Gemcitabine Plus IGF-1R拮抗剂（MK-0646）的随机，I / II次研究与吉西他滨加上奥尔洛替尼（MK-0646），用于高级胰腺腺癌的MK-0646

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Reham Abdel-Wahab; Gauri R. Varadhachary; Priya R. Bhosale; Xuemei Wang; David R. Fogelman; Rachna T. Shroff; Michael J. Overman; Robert A. Wolff; Milind Javle;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance) [J] . Halfdanarson Thorvardur R., Foster Nathan R., Kim George P., The oncologist . 2019,第5期

机译：未经处理的转移性胰腺腺癌患者的Panitumumab，Erlotinib和Gemcitabine的II期随机试验与奥尔洛替尼和吉西他滨，北中央癌症治疗组试验N064B（联盟）
2. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance) [J] . Thorvardur R. Halfdanarson, Nathan R. Foster, George P. Kim, The oncologist . 2019,第5期

机译：未经处理的转移性胰腺腺癌患者的Panitumumab，Erlotinib和Gemcitabine的II期随机试验与奥尔洛替尼和吉西他滨，北中央癌症治疗组试验N064B（联盟）
3. An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial. [J] . Gridelli C, Butts C, Ciardiello F, Clinical lung cancer . 2008,第4期

机译：国际，多中心，随机，III期研究对晚期非小细胞肺癌一线埃罗替尼，二线顺铂/吉西他滨与一线顺铂/吉西他滨，二线埃洛替尼进行二线研究：治疗原理和方案动态TORCH审判。
4. PHASE II OPEN-LABEL STUDY OF SINGLE-AGENT HYDROXYUREA FOR TREATMENT OF ADVANCED CUTANEOUS MAST CELL TUMORS IN DOGS [C] . Ken Rassnick, Renee Al-Sarraf, Dennis Bailey, Annual Conference of the Veterinary Cancer Society . 2009

机译：单药羟基脲的第II期开放标签研究，用于治疗犬晚皮腰肿瘤瘤
5. Multiscale Pharmacodynamic Studies of Combination Gemcitabine and Trabectedin for the Treatment of Pancreatic Cancer. [D] . Miao, Xin. 2017

机译：吉西他滨联合曲贝汀联合治疗胰腺癌的多尺度药效学研究。
6. Randomized phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma [O] . Reham Abdel-Wahab, Gauri R. Varadhachary, Priya R. Bhosale, 2018

机译：吉西他滨联合IGF-1R拮抗剂（MK-0646）与吉西他滨联合厄洛替尼联合或不联合MK-0646治疗晚期胰腺癌的随机I / II期研究
7. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104) [O] . Volker Heinemann, Ursula Vehling-Kaiser, Dirk Waldschmidt, 2012

机译：Gemcitabine Plus erlotinib随后Capecitabine与Capecitabine Plus erlotinib接下来是晚期胰腺癌中的吉西他滨：ArbeitsGemeinschaft Internistische Onkologie的随机阶段3试验的最终结果（Aio-PK0104）

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma

著录项

相似文献

相关主题

期刊订阅